Membrane Protein-Binding and Membrane-Inserting Chimeras for Cancer Therapy.

Area of Science:

• Biochemistry
• Molecular Biology
• Nanotechnology

Background:

• Aptamers and antibodies are crucial for cancer theranostics but struggle with tumor retention due to noncovalent interactions.
• The acidic tumor microenvironment poses challenges for drug accumulation and therapeutic effectiveness.

Purpose of the Study:

• To develop novel membrane protein-targeting and membrane-inserting (MBI) chimeras for improved cancer theranostics.
• To enhance the delivery of therapeutic agents like chlorin e6 (Ce6) into tumor cells.
• To overcome limitations of traditional molecular recognition tools in tumor microenvironments.

Main Methods:

• Conjugation of a membrane protein-targeting aptamer with a pH-responsive membrane-inserting domain (pHLIP).
• Creation of MBI chimeras designed to target tumor cells in acidic environments.
• In vivo evaluation of Ce6-loaded MBI chimeras (Sgc8-pHLIP) for photodynamic therapy efficacy.

Main Results:

• MBI chimeras demonstrated efficient binding to tumor cells in acidic conditions.
• Sgc8-pHLIP showed significantly enhanced photodynamic therapeutic efficacy compared to control constructs.
• The synergistic effect of membrane targeting and insertion improved drug delivery and retention.

Conclusions:

• MBI chimeras represent a promising strategy for precise cancer therapeutics.
• This approach enhances the efficiency of molecular recognition tools for cancer treatment.
• The study highlights the potential of combining targeting and membrane insertion for improved theranostics.